Xcout Intel
On Target Laboratories
On Target Laboratories, Inc. is a biotechnology company founded in 2010 and headquartered in West Lafayette, Indiana. It discovers and develops targeted intraoperative molecular imaging agents to illuminate cancer during surgery.
Subscribe to see On Target Laboratories’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
On Target Laboratories at a glance
On Target Laboratories is a biotechnology company headquartered in United States. Its most recent funding round, Series B, raised $44M in March 2018. Xcout tracks 12 named people at On Target Laboratories, including Bill Peters (President, Chief Executive Officer, and Board Member).
On Target Laboratories leadership
- Bill PetersPresident, Chief Executive Officer, and Board Member
- Rod MacLeodChief Financial Officer
- Tommy LeeSenior Vice President of Clinical Operations
- Anne FornicolaVice President of Chemistry, Manufacturing and Controls
- Catherine BrissonVice President of Regulatory Affairs and Quality
- Philip MacdonaldVice President of Market Access, Reimbursement and Health Economics
6 more named people on record for On Target Laboratories, with roles, board committees and tenure — see the full roster →
On Target Laboratories funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $44M | 3 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
On Target Laboratories competitors
A few of On Target Laboratories's closest competitors — see the full list of competitors and alternatives →
ImaginAb, Inc. is a global biotechnology company headquartered in California, with operations in Los Angeles and San Diego. It focuses on developing next-generation imaging and radiopharmaceutical products for cancer immunology.
ABSCINT is a clinical-stage biotechnology company that develops platform production processes for rapid creation of cold kits for molecular imaging in oncology and immunology. Headquartered in Belgium, the privately held firm focuses on innovative diagnostic and therapeutic applications using single-domain antibodies.
Lantheus Holdings, Inc. is a global pharmaceutical company dedicated to the development, manufacturing, and commercialization of advanced diagnostic and therapeutic agents. Their mission is to empower clinicians worldwide in the accurate diagnosis and effective treatment of a wide spectrum of conditions, particularly heart disease, various cancers, and other serious illnesses. Their current diagnostic portfolio features several key products: DEFINITY, a microbubble ultrasound contrast agent for cardiac evaluations; TechneLite, a technetium generator essential for nuclear medicine; Xenon-133, used to assess pulmonary function; Neurolite, which helps identify stroke-damaged areas in the brain; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 for detecting cardiovascular disease; and Gallium-67, utilized in identifying infections and cancerous tumors. They also offer the Automated Bone Scan Index, a tool for quantifying prostate cancer burden from bone scans; PYLARIFY, designed for visualizing lymph nodes, bone, and soft tissue metastases to detect recurrent or metastatic prostate cancer; and Cobalt (Co 57), a non-pharmaceutical radiochemical. In the therapeutic space, Lantheus provides AZEDRA, a radiopharmaceutical treatment for both adult and pediatric patients, and RELISTOR, a medication addressing opioid-induced constipation. The company's robust development pipeline includes promising innovations such as flurpiridaz F 18, an agent for assessing myocardial blood flow; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in both children and adults; PYLARIFY AI, an AI-powered medical device software for standardized quantitative analysis of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. Lantheus serves a diverse client base, including radiopharmacies, distributors, integrated delivery networks, hospitals, clinics, and group medical practices. They foster strategic collaborations with notable industry partners such as NanoMab Technology Limited, Bausch Health Companies, Inc., GE Healthcare Limited, Curium, Bayer AG, CytoDyn Inc., ROTOP, FUJIFILM, Regeneron Pharmaceuticals, Inc., and POINT Biopharma US Inc. Established in 1956, Lantheus Holdings, Inc. maintains its corporate headquarters in North Billerica, Massachusetts.
Spago Nanomedical is a clinical-stage pharmaceutical company that develops precision nanomedicine products for the diagnosis and treatment of cancer and other severe diseases. Its pipeline includes Tumorad, a targeted radionuclide therapy for various cancers, and SpagoPix, a polymeric contrast agent designed to improve the precision of MRI diagnostics.
MorphImmune Inc. is a biotechnology company focused on developing targeted oncology therapeutics. The company has corporate locations in Bothell, Washington, and West Lafayette, Indiana, and announced a definitive merger with Immunome.
OncXerna Therapeutics is a clinical-stage precision-oncology biotechnology company that develops RNA-based biomarkers and targeted cancer therapies. Its work is intended to help identify cancer patients most likely to benefit from particular treatments and support oncologists and pharmaceutical partners in treatment selection.
Get On Target Laboratories's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on On Target Laboratories in Xcout Intel
- 12 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access